OPR - Delayed Quote • USD MESO Jan 2025 0.500 call (MESO250117C00000500) Follow 1.0400 0.0000 (0.00%) At close: December 12 at 12:55 PM EST Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for MESO250117C00000500 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: MESO Three Leading Growth Companies In Australia With Insider Ownership Reaching 27% Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up After Almost 4 Years, FDA Says Mesoblast Phase 3 Therapy Data Can Support Resubmission For Serious Complications in Children Following Stem Cell Transplant United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD) Mesoblast Limited (NASDAQ:MESO) Q2 2024 Earnings Call Transcript Mesoblast First Half 2024 Earnings: EPS Beats Expectations, Revenues Lag Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023 Mesoblast Financial Results and Corporate Update Webcast United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
